PRX 012
Alternative Names: PRX-012Latest Information Update: 04 Apr 2023
At a glance
- Originator Prothena
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors; Protein aggregation modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 31 Mar 2023 Updated pharmacodynamics data from preclinical studies in Alzheimer's disease released by Prothena
- 14 Mar 2023 Pharmacodynamics data from preclinical studies in Alzheimer's disease released by Prothena
- 26 Apr 2022 PRX 012 receives Fast Track designation for Alzheimer's disease [SC,Injection] in Ireland